Full wire
Times are UTC. Priority tells you how much a story changes things. What the levels mean
Argenx will pay $550 million upfront and up to $595 million in milestones for Santa Cruz peptide developer Unnatural Products. No programs, targets or clinical candidates were disclosed, and closing is expected by the end of 2026.
SANTA CRUZ, CA · argenx and Unnatural Products announcement, 9 Nov 2026, as reported by BioPharm International and BioPharma Dive
Doctors quoted by Men's Health say people on GLP 1 drugs do not automatically need B12 supplements and tie any shortfall to eating less, not poor absorption. The report cites no data on how often deficiency occurs.
NEW YORK · Men's Health consumer health report quoting two physicians and a nutrition scientist, 9 Nov 2026
A GP at an online clinic told Mirror readers how to come off weight loss jabs. A BMJ review finds regain of about 0.8 kg a month after semaglutide and tirzepatide, and no tested taper exists in the sources checked.
LONDON · Mirror report, 9 Nov 2026; BMJ systematic review and meta-analysis (doi 10.1136/bmj-2025-085304), 7 Jan 2026
A LiveNow Fox report on Yahoo Health says people on GLP 1 drugs can enjoy Thanksgiving by filling half the plate with vegetables. The advice comes from a dietitian, the American Diabetes Association and UC Davis, and cites no study of holiday eating on these drugs.
SAN JOSE, CA · LiveNow Fox report carried by Yahoo Health, 9 Nov 2026, citing The Associated Press, a UC Davis release and the American Diabetes Association website
A medRxiv preprint from a deprived Hampshire GP practice reports the largest HbA1c falls in the six patients on insulin or GLP 1 drugs who attended four or more group sessions. Only 15 people took part, and there was no control group.
HAVANT, ENGLAND · medRxiv preprint by Bond, Sennett and Veighey, posted 9 Nov 2026, not peer reviewed
At The Liver Meeting 2026, IMPACT trial analyses showed up to 42.9% of patients on pemvidutide met three liver test targets together at 48 weeks, against 3.3% on placebo. The results rest on noninvasive tests, and 48 week safety data were not reported.
DENVER · Poster by Alkhouri et al. at The Liver Meeting 2026, Denver, 7 Nov 2026, as reported by HCPLive on 8 Nov 2026
A nurse practitioner's MassLive column says 3 in 10 of 1,000 peptide users went to an emergency room but names no survey. Its other warnings match what regulators have found.
WESTFIELD, MASS. · Westfield Health Bulletin opinion column by nurse practitioner Juanita Carnes, MassLive, 6 Nov 2026
Novo Nordisk now plans to sell its Wegovy pill in more than 20 countries by mid 2027, not end 2027, after third quarter pill sales of DKK 5.39 billion beat forecasts. The launch plan and the raised outlook are company projections.
COPENHAGEN · Novo Nordisk Q3 2026 interim report, 4 Nov 2026, as reported by Reuters via Medical Dialogues
Eli Lilly will offer Zepbound and Foundayo through Hims & Hers at its standard self pay prices, eight months after Hims moved away from compounded GLP 1 drugs. Financial terms, timing and patient numbers were not disclosed.
INDIANAPOLIS · Eli Lilly and Hims & Hers joint press release, 6 Nov 2026
Two Baker Donelson attorneys say doctors who prescribe or source unapproved peptides still face license, criminal, fraud and malpractice exposure, even after a federal policy paused FDA enforcement against pharmacies compounding six peptides.
WASHINGTON · Healio Orthopedics Today expert submission by Baker Donelson attorneys Gary W. Herschman and Mark Yacura, 6 Nov 2026
A Pharmacy Times review says 13 state Medicaid programs covered GLP 1 drugs for obesity in January 2026, down from 16, while Medicare relies on a temporary Bridge through 2027. Heart and kidney benefits stay tied to specific drugs and trials.
WASHINGTON · Pharmacy Times clinical review, 6 Nov 2026; KFF Medicaid GLP 1 analysis, Jan 2026; CMS memo of 21 Apr 2026 as reported by the American Hospital Association
Lilly's placebo controlled ATTAIN-OSA program of once daily oral orforglipron in obstructive sleep apnea with obesity or overweight is a Monday late breaker at AHA. No efficacy data were public beforehand.
CHICAGO · MedPage Today AHA meeting preview, 6 Nov 2026; ATTAIN-OSA design paper (PubMed) and ClinicalTrials.gov NCT06649045
Case reports and patient accounts describe skin that burns at a light touch on semaglutide and tirzepatide. Trials count a broader symptom, dysesthesia, more often with experimental retatrutide, but no study shows cause or frequency.
BOSTON · Daily Mail Health report, 5 Nov 2026, citing 2025 case reports and Phase 3 trial data
A pharmacist's review says the HHS policy cites human studies and a test certificate for BPC 157 without releasing them. All six peptides were included against FDA reviewer advice, and comments close November 13.
WASHINGTON · HHS enforcement discretion policy with Appendix B, October 2026; Science-Based Medicine analysis by pharmacist Scott Gavura, 5 Nov 2026
Hair loss is the most common of three GLP 1 concerns raised in a Straight Arrow News report, with the Zepbound label tying it to weight loss. NAION vision loss looks rare and unproven as a drug effect, and nail data are early.
NEW BRUNSWICK, NJ · Straight Arrow News report, 5 Nov 2026; Zepbound prescribing information on DailyMed
Kimberly-Clark CEO Mike Hsu says Rogaine is up 30% year to date and that GLP 1 adoption may be a driver. The company showed no buyer data, and doctors tie most shedding on these drugs to fast weight loss.
IRVING, TX · Kimberly-Clark third quarter 2026 earnings call, 5 Nov 2026, remarks by CEO Mike Hsu (call transcript)
Camurus says LUNAR-2 will test its monthly semaglutide depot CAM2056 against placebo in 150 people with obesity or overweight. Its earlier data came from 80 people, and the new trial will not compare the depot with weekly injections.
LUND, SWEDEN · Camurus press release, 3 Nov 2026; Camurus Phase 1b topline release, 10 Nov 2025
A post hoc VALIANT and VALE analysis presented at Kidney Week 2026 found adolescents on pegcetacoplan kept a 67.5% drop in proteinuria at 76 weeks with stable kidney function. The long term data have no placebo comparison.
DENVER · ASN Kidney Week 2026 abstract TH-OR070 (Dixon et al.), as reported by HCPLive, 4 Nov 2026; FDA orphan drug record for approval dates
Novo Nordisk says its Wegovy pill took about 80% of new U.S. prescriptions in the third quarter as it raised its 2026 outlook for a third time. The share figure is company reported, and U.S. Wegovy prices fell 30% to 35%.
BAGSVAERD, DENMARK · Novo Nordisk company announcement No 65/2026 (Q3 financial report) and Q3 earnings call, 4 Nov 2026
Three GPs quoted by the Daily Mail told people on weight loss jabs not to change their dose for Christmas. The UK Mounjaro leaflet sets missed dose rules, and no study cited measures planned festive pauses.
LONDON · Daily Mail column by Louise Atkinson, 4 Nov 2026; UK Mounjaro patient leaflet (Eli Lilly), revised Aug 2026
A UK GP told people on Mounjaro and Wegovy to use sharps bins, not recycling, after the BBC reported needles reaching a Coventry sorting plant. No national figures on discarded needles have been published.
COVENTRY, ENGLAND · Coventry Telegraph report, 3 Nov 2026, citing a BBC report on Sherborne Recycling in Coventry
The FDA's category 2 list cites deaths in studies of GHRP 2 and ipamorelin, without proven cause. The entries date to 2023, and the same page flags thin safety data for BPC 157 and five peptides now covered by an HHS policy.
SILVER SPRING, MD · FDA web page on bulk drug substances in category 2 of the compounding interim policies, content current as of 22 Apr 2026
Jyske Bank expects Novo Nordisk to raise the floor of its 2026 outlook, and consensus puts third quarter Wegovy pill sales at 4.6 billion kroner. All figures are analyst estimates made before the release.
COPENHAGEN · ad-hoc-news.de preview citing Jyske Bank, Sydbank, Morningstar and Bloomberg consensus via Ekstra Bladet, 3 Nov 2026
The ASA ruled that two Voy ads and one each from Juniper and MedExpress promoted prescription only weight loss tablets to the public, even though none named oral Wegovy. The MHRA welcomed the rulings.
LONDON · ASA rulings published 4 Nov 2026, as reported by The Independent and Chemist and Druggist
Zeus Hygia says its two week Metaberine study, which reported higher natural GLP 1 and lower glucose in 36 adults, is not weight loss evidence. The weight gap against placebo was about 0.35 kg.
HYDERABAD · International Journal of Clinical Trials paper, 28 Jul 2026; supplier comments to NutraIngredients, 2 Nov 2026
Apple Women's Health Study data presented at ASRM link combined GLP 1 and GIP drugs with cycles that shortened by 2.5 days and varied slightly less, with the largest gap in PMOS. The cohort is self reported and observational.
BALTIMORE · ASRM annual meeting presentation by Shruthi Mahalingaiah and colleagues, as reported by MedPage Today, 2 Nov 2026
Developers at Arecor, WuXi AppTec and Sai Life Sciences told Pharmaceutical Technology that changing a peptide's structure can help it survive the gut, but each gain brings tradeoffs in potency, solubility and manufacturing.
UNITED STATES · Pharmaceutical Technology feature by Cynthia A. Challener, 2 Nov 2026; FDA press release on Lipfendra, 17 Jul 2026
Men's Health reviewed the research behind 19 synthetic peptides. For the six now open to pharmacy compounding under an HHS policy, most support comes from animal or cell studies, and none is FDA approved.
WASHINGTON · Men's Health peptide guide, 29 Oct 2026; FDA Pharmacy Compounding Advisory Committee meeting page, 23 to 24 Jul 2026
Lilly's oral GLP 1 drug brought in $184 million in the third quarter, short of analyst forecasts. The company blames launch stocking and says U.S. demand more than tripled, while the Wegovy pill still leads on prescriptions.
INDIANAPOLIS · Eli Lilly third quarter 2026 earnings release, 29 Oct 2026; CFO comments and IQVIA data as reported by Chosun Biz, 2 Nov 2026
An HHS policy lets pharmacies compound six unapproved peptides under set conditions, but BoxingInsider reports that all six remain banned in sport and a prescription is no defense for licensed fighters.
WASHINGTON · BoxingInsider report, 30 Oct 2026, on the HHS interim compounding enforcement policy published in the Federal Register on 30 Oct 2026